Cordis will pay $235m upfront and up to $900m in additional milestone payments to acquire MedAlliance, the privately held Swiss developer of the Selution SLR sirolimus-eluting vascular balloon.
Under the terms of the agreement announced on 18 October, Cordis will invest $35m in MedAlliance and begin co-promoting Selution SLR immediately